Treatment and prophylaxis of tinea infections

Drugs

Volumn 52, Issue 2, 1996, Pages 209-224

  Piérard, Gérald E ^a,b   Arrese, Jorge E ^a   Piérard Franchimont, Claudine ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE; ANTIFUNGAL AGENT; CICLOPIROX; FLUCONAZOLE; GRISEOFULVIN; HALOPROGIN; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; MORPHOLINE DERIVATIVE; SAPERCONAZOLE; TERBINAFINE; TOLNAFTATE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG;

ANTIFUNGAL ACTIVITY; DERMATOMYCOSIS; DERMATOPHYTE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; NONHUMAN; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; REVIEW; SKIN INFECTION; SKIN MANIFESTATION; TINEA; TINEA CAPITIS; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS; TOPICAL DRUG ADMINISTRATION;

ARTHRODERMATACEAE; TINEA; TINEA CRURIS;

EID: 0029766573     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652020-00005     Document Type: Review

References (188)

1. Odds FC, Arai T, Disalvo AF, et al. Nomenclature of fungal diseases: a report and recommendations from a sub-committee of the International Society for Human and Animal Mycology. J Med Vet Mycol 1992; 30: 11-25
2. Elewski BE, Hazen PG. The superficial mycoses and the dermatophytes. J Am Acad Dermatol 1989; 21: 653-73
3. Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994; 31: S21-5
4. Degreef HJ, De Doncker PRG. Current therapy of dermatophytosis. J Am Acad Dermatol 1994; 31: S25-30
5. Georgii A, Korting HC. Antifungal susceptibility testing with dermatophytes. Mycoses 1991; 34: 193-9
6. Dahl MV. Dermatophytosis and the immune response. J Am Acad Dermatol 1994; 31: S34-41
7. Gip L. The in vitro determination of lingering antimycotic effect of two 1% omoconazole-nitrate cream formulations following single topical application. Mycoses 1988; 31: 155-8
8. Rurangirwa A, Piérard-Franchimont C, Piérard GE. Culture of fungi on cyanoacrylate skin surface strippings: a quantitative bioassay for evaluating antifungal drugs. Clin Exp Dermatol 1989; 14: 425-8
9. Rurangirwa A, Van Puyvelde L, Piérard GE. Culture de champignons sur couche cornée: évaluation de l'action anti-fongique de plantes médicinales rwandaises. Afr J Dermatol 1990; 3: 11-6
10. Aljabre SHM, Scott EM, Shankland GS. In vitro susceptibility of Trichophyton mentagrophytes arthroconidia to clotrimazole and griseofulvin in human corneocyte suspensions. Mycoses 1991; 34: 479-82
11. Piérard GE, Rurangirwa A, Piérard-Franchimont C. Bioavailability of fluconazole and ketoconazole in human stratum corneum and oral mucosa. Clin Exp Dermatol 1991; 16: 168-71
12. Piérard GE, Piérard-Franchimont C, Arrese Estrada J. Comparative study of the activity and lingering effect of topical anti-fungals. Skin Pharmacol 1993; 6: 208-14
13. Arrese JE, Schrooten P, De Doncker P, et al. Fungal cultures on cyanoacrylate skin surface stoppings as a dose-finding method for topical antifungals: a placebo-controlled study with itraconazole 0.25% and 0.50% cream. J Med Vet Mycol 1995; 33: 127-30
14. Piérard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995; 32: 429-35
15. Kerridge D. Mode of action of clinically important antifungal drugs. Adv Microb Physiol 1986; 27: 1-72
16. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994; 30: 677-98
17. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-33
18. Hay RJ Antifungal drugs on the horizon. J Am Acad Dermatol 1994; 31: S82-6
19. Gull K, Trinci APJ. Griseofulvin inhibits fungal mitosis. Nature 1973; 244: 292-4
20. Lenhart K. Griseofulvin resistance in dermatophytes. Experientia 1970; 26: 109-10
21. Artis WM, Odle BM, Jones HE. Griseofulvin-resistant dermatophytosis correlates with in vitro resistance. Arch Dermatol 1981; 117; 16-9
22. Harris R, Jones HE, Artis WM. Orally administered ketoconazole: route of delivery to stratum corneum. Antimicrob Agents Chemother 1983; 24: 876-82
23. Haria M, Bryson HM, Goa KL. Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996 Apr; 51 (4): 585-620
24. Wiedfeuer A, Seidl HP. The in vitro activity of fluconazole against fungi involved in dermal infections. Mycoses 1994; 37: 447-9
25. Van Cutsem J. An investigation of the in vitro activity and antifungal spectrum of itraconazole and terbinafine in relation to in vivo efficacy in dermatophytosis. J Mycol Med 1994; 4: 137-44
26. Hiratani T, Asagi Y, Matsusaka A, et al. in vitro antifungal activity of amorolfine, a new morpholine antimycotic agent. Jap J Antibiot 1991; 1006: 44-9
27. Polak-Wyss A. Mechanism of action of antifungals and combination therapy. J Eur Acad Dermatol Venereol 1995; 4 Suppl. 1: 11-6
28. Birnbaum JE. Pharmacology of the allylamines. J Am Acad Dermatol 1990; 23: 783-5
29. Monk J, Brogden RN. Naftifine: a review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs 1991; 42: 659-72
30. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259-84
31. Clayton YM. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994; 130 Suppl. 43: 7-8
32. Ryder NS, Frank I. Interaction of terbinafine with human serum and serum proteins. J Med Vet Mycol 1992; 30: 451-60
33. Barrett-Bee KJ, Lane AC, Turner RW. The mode of antifungal action of tolnaftate. J Med Vet Mycol 1986; 24: 155-60
34. Gupta MP, Kapur N, Bala I, et al. Studies on the mode of action of tolnaftate in Microsporum gypseum. J Med Vet Mycol 1991; 29: 45-52
35. Abrams BB, Hanel H, Hoehler T. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin Dermatol 1991; 9: 471-7
36. Polak A. Combination of amorolfine with various antifungal drugs in dermatophytosis. Mycoses 1993; 36: 43-9
37. Smith EB. Topical antifungal agents. Dermatol Clin 1984; 2: 109-13
38. Hernandez-Perez E. Bifonazole cream: once-a-day application every second day in tinea cruris and corporis. Dermatologica 1984; 169: 93-8
39. Lücker PW, Beubler E, Kukovetz WR, et al. Retention time and concentration in human skin of bifonazole and clotrimazole. Dermatologica 1984; 169 Suppl. 1: 51-6
40. Odds FC, Webster CE, Abbott AB. Antifungal relative inhibition factors: BAY 1-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole, and vibunazole (BAY n-7133)compared in vitro with nine established antifungal agents. J Antimicrob Chemother 1984; 14: 105-14
41. Jung EG, Bisco A, Azzollini E, et al. Fenticonazole cream once daily in dermatomycosis, a double-blind controlled trial versus bifonazole. Dermatologica 1988; 177: 104-8
42. Wheatley D, Richardson MD, Scott EM. Tinea infections treated with bifonazole gel. Mycoses 1988; 31: 471-5
43. Lackner TE, Clissold SP. Bifonazole: a review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs 1989; 38: 204-25
44. Alomar A, Videla S, Delgadillo J, et al. Flutrimazole 1% dermal cream in the treatment of dermatomycoses: a multicentre. double-blind, randomized, comparative clinical trial with bifonazole 1% cream. Dermatology 1995; 190: 295-300
45. Hay RJ, Roberts DT, Doherty VR, et al. The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin Exp Dermatol 1988; 13: 164-7
46. Torres-Rodriguez JM, Madrenys N, Nicolas MC. Non-traumatic topical treatment of onychomycosis with urea associated with bifonazole. Mycoses 1991; 34: 499-504
47. Arika T, Hase T, Yokoo M. Anti-Trichophyton mentagrophytes activity and percutaneous permeation of butenafine in guinea pigs. Antimicrob Agents Chemother 1993; 37: 363-5
48. Clayton YM, Connor BL. Comparison of clotrimazole cream, Whitefield's ointment and nystatin ointment for the topical treatment of ringworm infection, pityriasis versicolor, erythrasma and candidiasis. Br J Dermatol 1973; 89: 297-303
49. Finzi A, Fioroni A, Pretim PM. A double-blind evaluation of fenticonazole cream 2% and clotrimazole cream 1% in dermatomycoses. Mykosen 1986; 29: 41-4
50. Lassus A, Forstrom S, Salo O. A double-blind comparison of sulconazole nitrate 1% cream with clotrimazole 1% cream in the treatment of dermatophytoses. Br J Dermatol 1989; 108: 195-8
51. Smith EB, Breneman DL, Griffith RF, et al. Double-blind comparison of naftifine cream and clotrimazole betamethasone dipropionate cream in the treatment of tinea pedis. J Am Acad Dermatol 1992; 26: 125-7
52. Binet O, Soto-Melo J, Delgadillo J, et al. Flutrimazole 1% dermal cream in the treatment of dermatomycoses: a randomized multicentre, double blind, comparative trial with 1% clotrimazole cream. Mycoses 1995; 37: 455-9
53. Evans EGV. Acomparison of terbinafine (Lamisil®) 1% cream given for one week with clotrimazole (Canesten®) 1% cream given for four weeks, in the treatment of tinea pedis. Br J Dermatol 1994; 130 Suppl. 43: 12-4
54. Elewski B, Bergstresser PR, Hanifin J. Long-term outcome of patients with interdigital tinea pedis treated with terbinafine or clotrimazole. J Am Acad Dermatol 1995; 32: 290-2
55. Del Palacio A, Cuetara S, Rodriguez Noriega A. Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1%, and 2%: a phase II dose-finding pilot study. Mycoses 1995; 38: 317-28
56. Heel RC, Brogden RN, Speight TM, et al. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs 1978; 16: 177-201
57. Grigoriu D, Grigoriu A. Double-blind comparison of the efficacy, toleration and safety of tioconazole base 1% and econazole nitrate 1% creams in the treatment of patients with fungal infections of the skin or erythrasma. Dermatologica 1983; 166 Suppl. 1: 8-13
58. Kokoschka EM, Miebauer G, Mounari M, et al. Treatment of dermatomycoses with topical fenticonazole and econazole. Mykosen 1986; 29: 45-50
59. Millikan LE, Galen WK, Gewirtzman GM, et al. Naftifine cream 1% versus econazole cream 1% in a treatment of tinea cruris and tinea corporis. J Am Acad Dermatol 1988; 18: 52-6
60. Tullio V, Cuffini AM, Carlone NA. In vitro antifungal activities of new imidazole salts towards dermatophytes. Mycoses 1990; 33: 257-63
61. Albanese G, Di Cintio R, Giorgetti P, et al. Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder. Mycoses 1992; 35: 157-9
62. Cugnani HC, Akpata LE, Gugnani MK, et al. Isoconazole nitrate in the treatment of tropical dermatomycoses. Mycoses 1994; 37: 39-41
63. Greer DL, Jolly HW. Comparative trial of a two-dosage schedule of ketoconazole 2% cream for the treatment of tinea pedis. J Am Acad Dermatol 1987; 17: 53-6
64. Clayton YM, Knight AG. A clinical double-blind trial of topical miconazole against superficial fungal infections and erythrasma. Clin Exp Dermatol 1976; 1: 225-32
65. Cotterill JA, Evans LGV. Treatment of tinea corporis with miconazole. Br J Clin Pract 1978; 32: 13-4
66. Clayton YM, Gange RW, Mac-Donald DM, et al. A clinical double-blind trial of topical haloprogin and miconazole against superficial fungal infection. Clin Exp Dermatol 1979; 4: 65-74
67. Clayton YM, Hay RJ, McGibbon DH, et al. Double-blind comparison of the efficacy of tioconazole and miconazole for the treatment of fungal infection of the skin or erythrasma. Clin Exp Dermatol 1982; 7: 543-9
68. Tanenbaum L, Anderson C, Rosenberg MJ. Sulconazole nitrate 1.0% cream: a comparison with miconazole in the treatment of tinea pedis and tinea cruris/corporis. Cutis 1982; 30: 105-7
69. Fredriksson T. Treatment of dermatomycoses with topical tioconazole and miconazole. Dermatologica 1983; 166: 14-9
70. Nolting S, Rogalia K. Double-blind comparison of miconazole/corticosteroid combination versus miconazole in inflammatory dermatomycoses. Int J Dermatol 1995; 34: 125-8
71. Rollman O. Treatment of onychomycosis by partial nail avulsion and topical miconazole. Dermatologica 1982; 165: 54-61
72. Ramelet AA, Walker-Nasir E. One daily application of oxiconazole cream is sufficient for treating dermatomycoses. Dermatologica 1987; 175: 293-5
73. Melchinger W, Polak A, Müller J. The effects of amorolfine and oxiconazole on the ultrastructure of Trichophyton mentagrophytes: a comparison. Mycoses 1988; 33: 393-404
74. Ellis CN, Gammon WR, Goldfarb MT, et al. A placebo-control led evaluation of once-daily versus twice-daily oxiconazole nitrate (1%) cream in the treatment of tinea pedis. Curr Ther Res 1989; 46: 264-76
75. Jegasothy BV, Pakes GE. Oxiconazole nitrate: pharmacology, efficacy, and safety of a new imidazole antifungal agent. Clin Ther 1991; 13: 126-41
76. Palacin C, Tarrago C, Sacristan A, et al. Antifungal activity of sertaconazole in the cutaneous retention time test. J Mycol Med 1945; 5: 35-9
77. Tanenbaum L, Taplin D, Lavalle C, et al. Sulconazole nitrate cream 1% for treating tinea cruris and corporis. Cutis 1989; 44: 344-7
78. Van Cutsem J, Van Gerven F, Zaman R, et al. Terconazole: a new broad spectrum antifungal. Chemotherapy 1983; 29: 322-31
79. Marriott MS, Baird JRC, Brammer KW, et al. Tioconazole, a new imidazole-antifungal agent for the treatment of dermatomycoses. Dermatologica 1983: 166: 1-7
80. Clissold SP, Heel RC. Tioconazole: a review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs 1986; 31: 29-51
81. Hay RJ, MacKie RM, Clayton YM. Tioconazole nail solution: an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1987; 10: 111-5
82. Hay RJ, Clayton YM, Moore MK. A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol 1987; 12: 175-7
83. Polak AM. Kinetics of amorolfine in human nails. Mycoses 1993; 36: 101-3
84. Zaug M. Amorolfine nail lacquer: clinical experience in onychomycosis. J Eur Acad Dermatol Venereol 1995; 4 Suppl. 1: 23-30
85. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989; 14, 124-7
86. Greer DL, Jolly HW. Treatment of tinea cruris with topical terbinafine. J Am Acad Dermatol 1990; 23: 800-4
87. Millikan LE. Efficacy and tolerability of topical terbinafine in the treatment of tinea eruris. J Am Acad Dermatol 1990; 23: 795-9
88. Savin RC. Treatment of chronic tinea pedis (athlele's foot type) with topical terbinafine. J Am Acad Dermatol 1990; 23: 786-9
89. Evans EGV, James IGV, Joshipura RC. Two-week treatment of tinea pedis with terbinafine (Lamisil) 1% cream: a placebo controlled study. J Dermatol Treat 1991; 2: 95-7
90. Berman B, Ellis C, Leyden J, et al. Efficacy of a 1 week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. J Am Acad Dermatol 1992; 26: 956-60
91. Hill S, T Smith SG, Finlay AY. An investigation of the pharmacokinetics of topical terbinafine (Lamisil®) 1% cream. Br J Dermatol 1992; 127: 396-400
92. Jue SG, Dawson GW, Brogden RN. Ciclopirox olamine 1% cream: a preliminary review of its antimicrobial activity and therapeutic use. Drugs 1985; 29: 330-41
93. Kligman AM, Bogaert H, Cordero C, et al. Evaluation of ciclopirox olamine cream for the treatment of tinea pedis: multicenter, double-blind comparative studies. Clin Ther 1985; 7: 409-17
94. Bogaert H, Cordero C, Ollague W, et al. Multicenter double-blind clinical trials of cyclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris. J Int Med Res 1986; 14: 210-6
95. Ceschin-Roques C, Hanel H, Pruja-Bougaret S. Ciclopiroxolamine nail lacquer 8%: in vitro penetration through nails and in vitro effect on pig skin. Skin Pharmacol 1991; 4: 89-94
96. Suringa DWR. Treatment of superficial onychomycosis with topically applied glutaraldehyde. Arch Dermatol 1970; 102: 163-7
97. Aly R, Bayles C, Oakes RA. Topical griseofulvin in the treatment of dermatophytoses. Clin Exp Dermatol 1994; 19: 43-6
98. Mares D, Fasculo MP, Bruni A. Ultraviolet-mediated antimycotic activity of α-terthienyl on Microsporum cookei. J Med Vet Mycol 1990; 28: 469-77
99. Mares D, Romangoli C, Rossi R, et al. Antifungal activity of some 2.2′: 5′,2″-tertiophene derivatives. Mycoses 1994; 37: 377-83
100. Smith EB, Dickson JE, Knox JM Tolnaftate powder in prophylaxis of tinea pedis. South Med J 1979; 67: 776-8
101. Ishii M, Hamada T, Asai Y. Treatment of onychomycosis by ODT therapy with 20% urea ointment and 2% tolnaftate ointment. Dermatologica 1983; 167: 273-9
102. Kishore N, Mishra AK, Chansouria JPN. Fungitoxicity of essential oils against dermatophytes. Mycoses 1993; 36: 211-3
103. Pönnighaus JM, Gooskens V, Clayton Y, et al. Treatment of superficial mycoses in the tropics: results of a double-blind trial in Karonga District, Malawi. Mycoses 1944; 37 Suppl. 1: 101-4
104. Garg AP, Müller J. Inhibition of growth of dermatophytes by Indian hair oils. Mycoses 1992; 35: 363-9
105. Stiller MJ. Systemic drugs in the treatment of dermatophytoses. Int J Dermatol 1993; 32: 16-21
106. Meinholf W. Kinetics and spectrum of activity of oral antifungals: the therapeutic implications. J Am Acad Dermatol 1993; 29: S37-41
107. Crounse RG. Human pharmacology of griseofulvin: the effect of fat intake on gastrointestinal absorption. J Invest Dermatol 1961; 37: 529-33
108. Shah VP, Epstein WL, Riegelman S. Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Invest 1974; 53: 1673-8
109. Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in stratum corneum: study after oral administration in man. Arch Dermatol 1972; 106: 344-8
110. Daneshment TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14: 13-34
111. Hay RJ. Pharmacodynamic and pharmacokinetic evaluation of fluconazole in skin and nails. Int J Dermatol 1992: 31 Suppl. 2: 6-7
112. Faergemann J, Laufen H. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum), and ecerine sweat. Clin Exp Dermatol 1993; 18: 102-6
113. Wiedfeuer A, Faergemann J, Laufen H, et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994; 37: 127-30
114. Cauwenbergh G, De Doncker P, Stoops K, et al. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Rev Infect Dis 1987; 9: S146-52
115. Mathieu L, De Doncker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed: an investigation in onychomycosis. Clin Exp Dermatol 1991; 16: 374-6
116. Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in the human skin. J Am Acad Dermatol 1988; 18: 263-8
117. De Doncker P, Van Lint J, Dockx P, et al. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995; 56: 180-3
118. De Doncker P, Decroix J, Piérard GE, et al. Antifungal pulse therapy in onychomycosis: a pharmacokinetic/pharmacodynamic investigation of monthly cycles of 1 week pulse with itraconazole. Arch Dermatol 1996; 132: 34-41
119. Vanden Bossche H, Marichal P, Willemsens G, et al. Saperconazole: a selective inhibitor of the cytochrome P-450-dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes. Mycoses 1990; 33: 335-52
120. Zienicke H, Korting HC. Clinical efficacy and tolerability of saperconazole for tinea of glabrous skin: a report on four cases. Mycoses 1993; 36: 131-4
121. Dykes PJ, Thomas R, Finlay AY. Determination of terbinafine in nail samples during systemic treatment for onychomycosis. Br J Dermatol 1990; 123: 481-6
122. Lever LR, Dykes PJ, Thomas R, et al. How orally-administered terbinafine reaches the stratum corneum. J Dermatol Treat 1990; 1 Suppl. 2: 23-5
123. Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992; 126 Suppl. 39: 28-32
124. Faergemann J, Zehender H, Denouël J, et al. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250mg terbinafine orally once per day for four weeks. Acta Dermatol Venereol 1993; 73: 305-9
125. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993; 29: S50-4
126. Ottervanger JP, Stricker BHC. Loss of taste and terbinafine. Lancet 1992; 340: 728
127. Villars V V, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126 Suppl. 39: 61-9
128. Bickers DR. Antifungal therapy: potential interactions with other classes of drugs. J Am Acad Dermatol 1994; 31: S87-90
129. Ginsburg CM, Gan VN, Petruska M. Randomized controlled trial of intralesional corticosteroid and griseofulvin vs. griseofulvin alone for treatment of kerion. Pediatr Infect Dis 1987; 6: 1084-7
130. Arikian SR, Einarson TR, Kobelt-Ngyen G. A multinational analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130 Suppl. 43: 35-44
131. Davis R, Balfour JA. Terbinafine: a pharmacoeconomic evaluation of its use in superficial fungal infections. Pharmacoeconomics 1995; 8: 253-69
132. Sobh M, El-Agroudy A, Moustafa F, et al. Coadministration of ketoconazole to cyclosporin-treated kidney transplant recipients: a prospective randomized study. Am J Nephrol 1995; 15: 493-9
133. Bourlond A, Lachapelle JM, Aussems J, et al. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol 1989; 28: 410-2
134. Lambert DR, Siegle RJ, Camisa C. Griseofulvin and ketoconazole in the treatment of dermatophyte infections. Int J Dermatol 1989: 28: 300-4
135. Del Palacio Hernanz A, Lopez Gomez S, Gonzalez Lastra F, et al. A comparative double blind study of terbinafine (Lamisil®) and griseofulvin in tinea corporis and tinea cruris. Clin Exp Dermatol 1990; 15: 210-6
136. Hay RJ, Clayton YM, Moore MK, et al. Itraconazole in the management of chronic dermatophytosis. J Am Acad Dermatol 1990; 23: 561-4
137. Roseeuw D, Willemsen M, t'Kint R, et al. Itraconazole in the treatment of superficial mycoses - a double-blind study vs. placebo. Clin Exp Dermatol 1990; 15: 101-4
138. Saul A, Bonifaz A. Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules. J Am Acad Dermatol 1990; 23: 554-8
139. Katsambas A, Antoniou CH, Frangouli E, et al. Itraconazole in the treatment of tinea corporis and tinea cruris. Clin Exp Dermatol 1993; 18: 322-5
140. Budimulja U, Kuswadji K, Bramono S, et al. A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole. Br J Dermatol 1994; 130 Suppl. 43: 29-31
141. Degreef H, Mariën K, De Veytler H, et al. Itraconazole in the treatment of dermatophytoses: a comparison of 2 daily dosages. Rev Infect Dis 1987; 1: S104-8
142. Parent D, Decroix J, Heenen M. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. Dermatology 1994; 189: 378-81
143. Kagawa S. Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. Clin Exp Dermatol 1989; 14: 114-5
144. Jones TC. Overview of the use of terbinafine (Lamisil®) in children. Br J Dermatol 1995; 132: 683-9
145. Rippon JW. The changing epidemiology and emerging patterns of dermatophyte species. Curr Top Med Mycol 1985; 1: 209-34
146. Leyden JL. Tinea pedis pathophysiology and treatment. J Am Acad Dermatol 1994; 31: S31-3
147. Van Hecke E, Van Cutsem J. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea pedis and tinea manuum. Mycoses 1988; 31: 641-9
148. Savin RC, Zaias N. Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind placebo-controlled trial. J Am Acad Dermatol 1990; 23: 804-7
149. Hay RJ, Logan RA, Moore MK, et al. A comparative study of terbinafine versus griseofulvin in 'dry-type' dermatophyte infections. J Am Acad Dermatol 1991; 24; 243-6
150. White JE, Perkins PJ, Evans EGV. Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum. Br J Dermatol 1991; 125: 260-2
151. De Keyser P, De Backer M, Massart DL, et al. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind multicentre study. Br J Dermatol 1994; 130 Suppl. 43: 22-5
152. Decroix J. Tinea pedis (moccasin-type) treated with itraconazole. Int J Dermatol 1995; 34: 122-4
153. Hay RJ, McGregor JM, Wuite J, et al. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 100 mg/day in plantar-type tinea pedis. Br J Dermatol 1995; 132: 604-8
154. Legendre R, Esola-Macre J. Itraconazole in the treatment of tinea capitis. J Am Acad Dermatol 1990; 23: 559-60
155. Elewski BE. Tinea capitis: itraconazole in Trichophyton tonsurans infections. J Am Acad Dermatol 1994; 31: 65-7
156. Lopez-Gomez S, Del Palacio A, Van Cutsem J, et al. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. Int J Dermatol 1994; 33: 743-7
157. Haroon TS, Hussain I, Mahmoud A, et al. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis. Br J Dermatol 1992; 126 Suppl. 39: 47-50
158. Suarez SM, Silvers DN, Scher RK, et al. Histologic evaluation of nail clippings for diagnosing onychomycosis. Arch Dermatol 1991; 127: 1517-9
159. Midgley G, Moore MK, Cook JC, et al. Mycology of nail disorders. J Am Acad Dermatol 1994; 31: S68-73
160. Piérard GE, Arrese JE, Pierre S, et al. Diagnostic microscopique des onychomycoses. Ann Dermatol Venereol 1994; 121: 25-9
161. Arrese JE, Piérard-Franchimont C, Greimers R, et al. Fungi in onychomycosis: a study by immunohistochemistry and dual How cytometry. J Eur Acad Dermatol Venereol 1995; 4: 123-30
162. Piérard GE, Arrese JE, De Doncker P, et al. Present and potential diagnostic techniques in onychomycosis. J Am Acad Dermatol 1996; 34: 273-7
163. Piérard GE, Arrese Estrada J, Piérard-Franchimont C. Treatment of onychomycosis: traditional approaches. J Am Acad Dermatol 1993; 29: S41-5
164. Brein J. Effective topical method of therapy for onychomycosis. Cutis 1981; 27: 69-76
165. Faergemann J, Swanbeck G. Treatment of onychomycosis with a propylene glycol urea-lactic acid solution. Mycoses 1989; 32: 536-40
166. Cohen PR, Scher RK. Topical and surgical treatment of onychomycosis. J Am Acad Dermatol 1994; 31: S74-7
167. Faergeman J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32: 750-3
168. Haneke E, Tausch I, Bräutigam M, et al. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32: 72-7
169. Roseeuw D, De Doncker P. New approaches to the treatment of onychomycosis. J Am Acad Dermatol 1993; 29: 545-50
170. Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol 1994; 31: S78-81
171. Coldiron B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992; 128: 909-10
172. Kuokkanen K, Alvara S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3: 115-7
173. Meléndez M, Siles L, Montero-Gei F. Fluconazole treatment of onychomycosis: traditional approaches. J Am Acad Dermatol 1993; 29: 541-5
174. Nahass GT, Sisto M. Onychomycosis: successful treatment with once weekly fluconazole. Dermatology 1993; 186: 59-61
175. Hay RJ, Clayton YM, Moore MK, et al. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119: 359-66
176. Walsoe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis: open and double-blind studies. Acta Dermatol Venereol 1990; 70: 137-40
177. Piepponen T, Blomqvist K, Brandt H, et al. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chem 1992; 29: 195-205
178. Willemsen M, De Doncker P, Willems J, et al. Post-treatment itraconazole levels in the nail. J Am Acad Dermatol 1992; 26: 731-5
179. André J, De Doncker P, Laporte M, et al. Onychomycosis caused by Microsporum canis. treatment with itraconazole. J Am Acad Dermatol 1995; 32: 1052-3
180. Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol 1989; 14: 120-3
181. Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992; 304: 1151-4
182. Van der Schroeff JG, Cirkel PKS, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126 Suppl. 39: 36-9
183. Albanese G, Di Cintio R, Martini C, et al. Short therapy for tinea unguium with terbinafine: four different courses of treatment. Mycoses 1995; 38: 211-4
184. Matsumoto T, Tanuma H, Kaneko S, et al. Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium. Mycoses 1995; 38: 135-44
185. Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595-600
186. De Doncker P, Piérard GE. Acquired nail beading in patients receiving itraconazole: an indicator of faster nail growth? A study using optical profilometry. Clin Exp Dermatol 1994; 19: 404-6
187. Weitzman I, Summerbel R. The dermatophytes. Clin Microbiol Rev 1995; 8: 240-59
188. Piérard-Franchimont C, De Doncker P, Van de Velde V, et al. Paradoxical response to itraconazole treatment in a patient with onychomycosis caused by Microsporum gypseum. Ann Soc Belge Med Trop 1995; 75: 211-7